NCT07065578Not yet recruiting
Optimization of STAR
Optimization of the STAR Intervention on Self-care Symptom Management in Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 15 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this study is optimize the STAR (SympTom mAnagement self-caRe) intervention to support patients with HF in staying healthy, and particularly in self-monitoring and managing symptoms. The STAR intervention includes promising components aiming at improving patient outcomes in terms of interference of bothersome symptoms, self-care, quality of life (QoL) and healthcare utilization. In this study, the intervention components are tested in an optimization trial in 320 patients with HF from 8 HF clinics in the Netherlands. This study will result in an optimized STAR intervention, composed of the best components, that is effective, scalable, and efficient to improve patient outcomes and can be used in HF clinics.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- First submitted
- 19 Jun 2025
- Start date
- Jul 2025
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- UMC Utrecht
- Diseases
- Heart failure
- NCT number
- NCT07065578
What you commit to
- Study type: Interventional
- Planned participants: 320
- From Jul 2025 to the primary completion date, 31 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participants living in a care facility (e.g. nursing home, revalidation center).
- Language barrier preventing sufficient understanding and communication in Dutch.
- Participants who are hospitalized during inclusion.
Who the study is looking for
- Diagnosed with HF (irrespective of ejection fraction) and symptomatic NYHA class II or III.
- 18 years or older.
- Willing and able to provide written informed consent.
- Life expectancy \>6 months.
- Optimal medical HF treatment following ESC HF guidelines (i.e. 'patients with stable HF').
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.